MD Tirzepatide

Tirzepatide Research: Mechanism, Trial Evidence, and Head-to-Head Data

The short version

Tirzepatide activates two hormone receptors at once — GIP and GLP-1 — both part of the body's meal-response system. Activating both produces bigger effects on blood sugar, weight, and appetite than activating GLP-1 alone. This has been confirmed across multiple large clinical trials. In people with type 2 diabetes, it cut blood sugar markers more than any previously approved comparable medicine in head-to-head studies. In people with obesity, it reduced body weight by roughly 20 percent over 72 weeks. More recently, trials have shown it can resolve fatty liver disease, reduce the severity of sleep apnea, and improve outcomes in a form of heart failure. The research below summarises the key findings, with every quantitative claim cited.

Tirzepatide mechanism of action

Tirzepatide is a 39-amino-acid synthetic peptide engineered from the native GIP sequence, with a fatty-diacid moiety attached via a lysine side chain. The fatty-diacid arm confers high albumin-binding affinity and a plasma half-life of approximately five days, supporting once-weekly dosing [1].

It activates both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) with a single molecule. GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are incretin hormones — gut-derived signals released after eating that amplify the insulin response when blood sugar rises. Engaging both simultaneously enhances glucose-dependent insulin secretion, suppresses glucagon (the counter-regulatory hormone that raises blood sugar), slows gastric emptying, and reduces appetite through central nervous system pathways.

In vitro signalling assays established that tirzepatide is an imbalanced dual agonist, engaging the GIP receptor more fully than the GLP-1 receptor, and exhibiting biased GLP-1 receptor signalling that favours cAMP generation over beta-arrestin recruitment (meaning it preferentially activates the cellular pathway that amplifies insulin secretion, rather than the pathway that dampens receptor sensitivity) [2]. Separately, mouse experiments showed that GIPR agonism contributes to insulin sensitisation in adipose tissue independently of GLP-1-driven weight loss [26].

Cryo-electron microscopy revealed the structural basis of this dual engagement, showing tirzepatide simultaneously occupying distinct receptor pockets on both the GIP and GLP-1 receptors [27].

Glycaemic efficacy in type 2 diabetes — the SURPASS programme

The SURPASS phase 3 programme tested tirzepatide across multiple type 2 diabetes populations.

SURPASS-1 established tirzepatide as monotherapy in adults with type 2 diabetes inadequately controlled by diet and exercise, producing substantial dose-dependent reductions in HbA1c and body weight versus placebo [28].

SURPASS-2 was the head-to-head trial against semaglutide 1 mg in 1,879 adults with type 2 diabetes over 40 weeks. Tirzepatide at 5, 10, and 15 mg once weekly reduced HbA1c by an estimated -2.01, -2.24, and -2.30 percentage points respectively, versus -1.86 percentage points with semaglutide (tirzepatide noninferior and superior at all doses). Body-weight reductions were 1.9, 3.6, and 5.5 kg greater with tirzepatide than semaglutide [3].

SURPASS-6 compared tirzepatide against prandial insulin lispro added to basal insulin. At 52 weeks, tirzepatide achieved an HbA1c change of -2.1% versus -1.1% for insulin lispro, with 68% versus 36% reaching HbA1c below 7.0%, and substantially less hypoglycaemia [29].

Across the SURPASS-1 to -5 trials, 43–82% of participants assigned to tirzepatide achieved the composite endpoint of HbA1c below 7.0% plus at least 5% weight loss without hypoglycaemia, compared with 4–5% with placebo [30].

Tirzepatide vs semaglutide

The most comprehensive head-to-head comparison in obesity is SURMOUNT-5 (n=751 adults with obesity but without type 2 diabetes). Participants received the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) once weekly for 72 weeks. The mean weight change at week 72 was -20.2% with tirzepatide versus -13.7% with semaglutide (P<0.001). Tirzepatide also produced a greater reduction in waist circumference and higher proportions reaching weight-loss thresholds of 10%, 15%, 20%, and 25% [5].

In the diabetes setting, SURPASS-2 established superiority over semaglutide 1 mg for both HbA1c and body weight [3]. An indirect treatment comparison in people with obesity and type 2 diabetes found tirzepatide 10 and 15 mg associated with significantly greater weight, BMI, and HbA1c reductions versus semaglutide 2.4 mg [31].

Real-world cardiovascular outcomes in type 2 diabetes appear broadly comparable between the two agents; a 2026 analysis of US insurance data (multiple propensity-matched cohorts) found tirzepatide versus dulaglutide had a hazard ratio for major adverse cardiovascular events of 0.87 (95% CI 0.75–1.01), with tirzepatide and semaglutide not significantly different against each other (HR 1.06, 95% CI 0.95–1.18) [32].

Beyond glycaemia — MASH, sleep apnea, and heart failure

SYNERGY-NASH (NCT04166773) enrolled adults with metabolic dysfunction-associated steatohepatitis (MASH — a progressive inflammatory fatty liver disease, formerly called NASH) and moderate-to-severe liver fibrosis. Once-weekly tirzepatide at 5, 10, and 15 mg led to MASH resolution without worsening of fibrosis at higher rates than placebo over 52 weeks [8]. A post hoc subgroup analysis found up to 73% of participants resolved MASH without worsening fibrosis, with significant fibrosis improvement seen at 5 mg and 15 mg in participants with stage 3 fibrosis [33].

SURMOUNT-OSA (NCT05412004) enrolled adults with obesity and moderate-to-severe obstructive sleep apnea. Tirzepatide at 10 or 15 mg once weekly over 52 weeks reduced the apnea-hypopnea index (AHI — the number of breathing interruptions per hour of sleep, used to measure sleep apnea severity) by 25.3 events per hour in participants not using a breathing device (PAP), and by 29.3 events per hour in those using one, versus roughly 5 events per hour with placebo [9].

SUMMIT (NCT04847557) enrolled patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Tirzepatide reduced heart-failure events and improved functional status versus placebo [10]. A cardiac MRI substudy found tirzepatide versus placebo reduced left ventricular mass by 11 g (95% CI -19 to -4 g; P=0.004) and paracardiac adipose tissue by 45 mL (95% CI -69 to -22 mL; P<0.001) over 52 weeks [34].

A 2025 network meta-analysis of 56 randomised controlled trials (60,307 patients) confirmed that both tirzepatide and semaglutide achieved greater than 10% total body weight loss versus placebo, and noted tirzepatide's specific efficacy for remission of obstructive sleep apnea and MASH [11].

Recent studies (2024–2025)

The most recent primary publications in the Tirzepatide references list include:

  • Aronne LJ, et al. SURMOUNT-5 head-to-head versus semaglutide in obesity: -20.2% versus -13.7% at 72 weeks. N Engl J Med 2025 [5].
  • Packer M, et al. SUMMIT: reduced heart-failure events and improved status in HFpEF with obesity. N Engl J Med 2025 [10].
  • Kramer CM, et al. SUMMIT CMR substudy: tirzepatide reduced LV mass and paracardiac adipose tissue. J Am Coll Cardiol 2025 [34].
  • Jastreboff AM, et al. SURMOUNT-1 extended follow-up: sustained weight reduction and reduced diabetes progression. N Engl J Med 2025 [35].
  • Samms RJ, et al. Annual Review of Physiology — mechanistic rationale for dual-incretin therapeutics. Annu Rev Physiol 2025 [36].
  • Look M, et al. SURMOUNT-1 DXA substudy: approximately 75% of weight lost was fat mass and approximately 25% lean mass. Diabetes Obes Metab 2025 [14].